BioCentury
ARTICLE | Product Development

Deciding factors in the shifting MS treatment landscape

The new drugs in MS show injectables can compete with orals. The next compounds will test that further

October 25, 2019 11:04 PM UTC
Updated on Oct 28, 2019 at 7:50 PM UTC

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out.

Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) is challenging the oral paradigm, overturning the conventional wisdom that oral is better...

BCIQ Company Profiles

Novartis AG